Ticagrelor to prevent restenosis: New drug for an old hypothesis?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 12, 2010, Pages 2320-2322

  Cayla, Guillaume ^a   Montalescot, Gilles ^a   Collet, Jean Philippe ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

platelet receptor blockers; restenosis; stent

Indexed keywords

CLOPIDOGREL; CORTICOSTEROID; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TICAGRELOR; ZOTAROLIMUS;

DRUG ELUTING STENT; DRUG MECHANISM; EDITORIAL; INFLAMMATION; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ADENOSINE; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CELL PROLIFERATION; CORONARY RESTENOSIS; FIBRINOLYTIC AGENTS; HUMANS; MICE; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS; TUNICA INTIMA;

EID: 78650329217     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.216267     Document Type: Editorial

References (12)

1. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angio-plasty. J Am Coll Cardiol. 1991;6(suppl B):77B-88B.
2. Farb A, Sangiorg G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52. (Pubitemid 29035956)
3. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol. 2006;46:277-300.
4. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudb-jartsson T, Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:1810-1815.
5. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE, Storey RF. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation. 2009;119:116-122.
6. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999; 100:799-806.
7. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL BE, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS; Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826-2832.
8. Patil SB, Jackman LE, Francis SE, Judge HM, Nylander S, Storey RF. Ticagrelor effectively and reversibly blocks murine platelet P2Y12 mediated thrombosis and demonstrates requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol. 2010;30:2385-2391.
9. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. The TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
11. Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation. 2010;122:1049-1052.
12. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056-1067.